Meeting 1: Ranking FDA Product Categories Based on Health Consequences, Phase II

Meeting Information

Project Title:	Ranking FDA Product Categories Based on Health Consequences, Phase II
PIN:	BEST-K-08-03-B
Major Unit:	Division of Behavioral and Social Sciences and Education Division on Earth and Life Studies Institute of Medicine
Sub Unit:	Board on Environmental Studies & Toxicology
RSO:	Mantus, Ellen

Subject/Focus Area:

Meeting 1 April 6, 2009 - April 7, 2009 Keck Center 500 5th Street, NW Washington D.C. 20001

If you would like to attend the sessions of this meeting that are open to the public or need more information please contact:
Contact Name: Nola Golson
Email: pgolson@nas.edu
Phone: 202-334-1669
Fax: 202-334-2752

Agenda: This meeting is closed in its entirety.
Closed Session Summary Posted After the Meeting The following committee members were present at the closed sessions of the meeting: Robert Lawrence (chair) Jeffrey Bender (via teleconference) Francisco Diez-Gonzalez Kathryn Edwards Susan Ellenberg Paul Fischbeck Karen Jenni (via teleconference) Helen Jensen Robin Keller James McKean David Meltzer (via teleconference) Sanford Miller Richard Platt (via teleconference) John Watson The following topics were discussed in the closed sessions: 1) Standard NRC discussion of policies, procedures, potential bias and conflict of interest. 2) Committee’s statement of task, approach, and letter report. 3) Agenda for Workshop I at which product categories and risk attributes will be finalized. 4) Schedule for future committee meetings. The following materials (written documents) were made available to the committee in the closed sessions: 1. FDA. 2009. FDA Comments on NAS “Letter Report on the Development of a Model for Ranking FDA Product Categories on the Basis of Health Risks.” April 3, 2009. Date of posting of Closed Session Summary: April 16, 2009